NeuroSense "PrimeC" Market size expansion of Several Folds by 2034

[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on PrimeC (NeuroSense) providing insights into the drug market landscape and market forecast of PrimeC upto 2034. The report, titled "PrimeC Sales Forecast, and Market Size Analysis - 2034" is now available for review and analysis.

Are you interested in finding out the projected market size of PrimeC in 2034? PrimeC Market Forecast
https://www.delveinsight.com/report-store/primec-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Key Factors Driving PrimeC Growth
1. Market Share Gains and New Patient Starts
• PrimeC is an extended-release oral fixed-dose combination of ciprofloxacin and celecoxib developed by NeuroSense Therapeutics to address multiple pathological mechanisms in amyotrophic lateral sclerosis (ALS), such as neuroinflammation, iron dysregulation, and miRNA dysfunction.
• In the Phase IIb PARADIGM trial, PrimeC demonstrated statistically significant slowing of ALS progression and survival benefits: progression slowed by ~33-37% versus placebo, with improved survival in treated patients.

2. Expansion Across Key Indications
• PrimeC has received Orphan Drug Designation from both the US FDA and the European Medicines Agency, which can provide incentives such as fee waivers, protocol assistance, and market exclusivity (e.g., 7 years in the US and 10 years in Europe upon approval).
• The US FDA has authorized a pivotal Phase III trial (PARAGON), planned to enroll ~300 ALS participants following positive Phase IIb feedback a key step toward potential approval.

The PrimeC Market Report offers projected sales forecasts for PrimeC for indications until 2034, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products indication. It also covers analyst views along with market drivers and barriers.
NeuroSense's PrimeC is serving as a beacon of hope for the patients suffering from the Parkinson's Disease.

What is a PrimeC Prescribed for?
PrimeC is an experimental prescription drug being developed primarily for the treatment of Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disorder that affects nerve cells responsible for controlling voluntary muscle movement.

PrimeC is designed to help slow the progression of ALS and potentially improve patient outcomes by targeting several biological pathways involved in the disease. ALS gradually damages motor neurons in the brain and spinal cord, leading to muscle weakness, loss of mobility, and difficulty speaking, swallowing, and breathing.

The report extensively covers the details and developments related to PrimeC, capturing important highlights on developmental pipeline, regulatory status and special designations of PrimeC, route of administration, safety and efficacy details.

PrimeC Market Assessment
This report provides a detailed market assessment of PrimeC for Parkinson's Disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2028 to 2034.

PrimeC Clinical Assessment
The report provides the clinical trials information of PrimeC for Parkinson's Disease covering trial interventions, trial conditions, trial status, start and completion dates. The report also includes important insights on regulatory milestones and other developmental activities related.

Do you know your drug's competitive positioning against PrimeC? PrimeC Drugs Insights
https://www.delveinsight.com/sample-request/primec-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

PrimeC Recent Developments in the Treatment Landscape
• In February 2026, NeuroSense Therapeutics Ltd., a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, announced the availability of additional long-term survival data from its previously completed PARADIGM Phase IIb clinical trial evaluating PrimeC in patients with amyotrophic lateral sclerosis (ALS).
• In September 2025, Recipharm, a leading global contract development and manufacturing organization (CDMO) partnered with NeuroSense Therapeutics to develop PrimeC, an advanced fixed-dose combination tablet designed to target multiple disease mechanisms in Amyotrophic Lateral Sclerosis (ALS).

PrimeC Competitive Landscape
The report offers insights into the key players and companies actively engaged in the development of the specified indication. It provides valuable information regarding the competitive positioning of the PrimeC.

PrimeC Market Size in the US
A dedicated section of the report focuses on the expected market size of PrimeC for the United States. DelveInsight's analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.

Key Highlights of PrimeC:
• The report contains forecasted sales of PrimeC for indication till 2034.
• Comprehensive coverage of the late-stage emerging therapies for Parkinson's Disease.
• The report also features the qualitative and quantitative analysis with analysts as well as KOL views for PrimeC in Parkinson's Disease.
Stay ahead in competition by leveraging insights on PrimeC market Report: Download PrimeC Market Report
https://www.delveinsight.com/sample-request/primec-emerging-drug-insight-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Why you should buy PrimeC Market Report:
• The report provides future market assessments for PrimeC for Parkinson's Disease in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts' views, detailed overview of market competitors, and short analysis of other emerging therapies in Ulcerative Colitis.
• Leading PrimeC for Parkinson's Disease forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the PrimeC
• Discover the competitive landscape of PrimeC through 7MM
• Get a Thorough Analysis of the PrimeC Development pipeline, Safety & Efficacy of the PrimeC, and ROA
• Thorough PrimeC market forecast will help understand how drug is competing with other emerging PrimeC
• Get analysis of the PrimeC clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
• Drug Market forecasts are calculated after taking into consideration KOL viewpoints

Related Reports By DelveInsight:

Parkinson's Disease Pipeline https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's, "Parkinson's Disease Pipeline Insight, 2026" report provides comprehensive insights about 130+ companies and 150+ pipeline drugs in Parkinson's Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.
It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.